INTRODUCTION

- Targeted prostate biopsy can be performed using visual-estimation (cognitive) targeting or MRI-ultrasound fusion platforms.
- We aimed to compare cancer detection of these two approaches performed by a large number of surgeons of varying expertise.

METHODS

- A prospective prostate cancer diagnosis registry identified 603 men who had undergone cognitive or image-fusion targeted transperineal biopsy for PI-RADS v2 score of $>/>=3$; a score of 3 required PSA-density $>/>=0.12\text{ng/mL/mL}$ (April 2017 - July 2019).
- Image-fusion was performed using the BiopSee® platform (Medcom) which utilises elastic registration.
- Propensity score matching (1:1) was performed by age, PSA, PSA-density, prostate volume, number of target lesions, operator grade, PI-RADS score and number of cores (caliper=0.25).
- Operator experience included senior urologists, trainee urologists or others (e.g. nurse practitioners).
- Detection rates of clinically significant (cs) and insignificant (ci) prostate cancer (PCa) were compared both overall and in subsets using Fisher’s Exact test.
- The threshold of csPCa used was Gleason $/>/>=3+4$.
- The number of cores taken was compared using the Mann-Whitney U test.

<table>
<thead>
<tr>
<th>Age</th>
<th>66.7 years (60.5 – 72)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSA</td>
<td>7.5ng/mL (5.5 – 10.8)</td>
</tr>
<tr>
<td>Prostate Volume</td>
<td>43mL (32-59)</td>
</tr>
<tr>
<td>PSA-density</td>
<td>0.17 ng/mL/mL (0.11-0.28)</td>
</tr>
</tbody>
</table>

Table 1. Overall Baseline Demographics (Median (IQR))

RESULTS

- Targeted transperineal prostate biopsy was performed for 845 lesions (cognitive: 261, image-fusion: 584) in 603 patients (cognitive: 185, image-fusion: 418).
- There was no overall difference in cs or ciPCa detection rates between cognitive and image-fusion targeting (242 pairs; $p=1.00$).
- Significantly more cores were taken when biopsies were performed cognitively (6; IQR: 5-8) than using image-fusion (6; IQR: 4-6) ($p<0.0001$).
- Senior urologists had a significantly higher detection rate of csPCa using image-fusion targeted biopsy (cognitive: 27.8%, image-fusion: 55.6%; 54 pairs; $p=0.006$).
- There was no significant difference when biopsies were conducted by trainee urologists (143 pairs; $p=0.1$) or other operators (17 pairs; $p=0.73$).
- There was no difference between cognitive and image-fusion for prostates <40mL (107 pairs; $p=0.49$), 40-80mL (94 pairs; $p=1.00$) or >80mL (20 pairs; $p=0.73$).
- Similarly, there was no difference when there was one target lesion (109 pairs; $p=0.54$) or two or more target lesions (133 pairs; $p=0.54$).

CONCLUSIONS

- We found no difference in overall cancer detection rates between cognitive targeted and image-fusion targeted transperineal biopsy, although in our series more cores were taken using cognitive targeting.
- Senior urologists had a significantly higher csPCa detection rate using image-fusion targeting.
- Choice of biopsy technique should be dependent on operator experience.